150 related articles for article (PubMed ID: 8207840)
1. Inhibition of p53-mediated transactivation by E6 of type 1, but not type 5, 8, or 47, human papillomavirus of cutaneous origin.
Kiyono T; Hiraiwa A; Ishii S; Takahashi T; Ishibashi M
J Virol; 1994 Jul; 68(7):4656-61. PubMed ID: 8207840
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells.
Pim D; Storey A; Thomas M; Massimi P; Banks L
Oncogene; 1994 Jul; 9(7):1869-76. PubMed ID: 8208532
[TBL] [Abstract][Full Text] [Related]
3. p53-Dependent and -independent transactivation by the E6 protein of human papillomavirus type 16.
Akutsu N; Shirasawa H; Asano T; Isono K; Simizu B
J Gen Virol; 1996 Mar; 77 ( Pt 3)():459-63. PubMed ID: 8601782
[TBL] [Abstract][Full Text] [Related]
4. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein.
Mietz JA; Unger T; Huibregtse JM; Howley PM
EMBO J; 1992 Dec; 11(13):5013-20. PubMed ID: 1464323
[TBL] [Abstract][Full Text] [Related]
5. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
Mansur CP; Marcus B; Dalal S; Androphy EJ
Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro.
Nakagawa S; Watanabe S; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Virology; 1995 Oct; 212(2):535-42. PubMed ID: 7571423
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p53 DNA binding by human papillomavirus E6 proteins.
Lechner MS; Laimins LA
J Virol; 1994 Jul; 68(7):4262-73. PubMed ID: 8207801
[TBL] [Abstract][Full Text] [Related]
8. Telomerase activation by the E6 gene product of human papillomavirus type 16.
Klingelhutz AJ; Foster SA; McDougall JK
Nature; 1996 Mar; 380(6569):79-82. PubMed ID: 8598912
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of serum- and calcium-induced terminal differentiation of human keratinocytes by HPV 16 E6: study of the association with p53 degradation, inhibition of p53 transactivation, and binding to E6BP.
Sherman L; Itzhaki H; Jackman A; Chen JJ; Koval D; Schlegel R
Virology; 2002 Jan; 292(2):309-20. PubMed ID: 11878933
[TBL] [Abstract][Full Text] [Related]
10. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53.
Hoppe-Seyler F; Butz K
J Virol; 1993 Jun; 67(6):3111-7. PubMed ID: 8388491
[TBL] [Abstract][Full Text] [Related]
11. Transactivation of prothymosin alpha and c-myc promoters by human papillomavirus type 16 E6 protein.
Kinoshita T; Shirasawa H; Shino Y; Moriya H; Desbarats L; Eilers M; Simizu B
Virology; 1997 May; 232(1):53-61. PubMed ID: 9185588
[TBL] [Abstract][Full Text] [Related]
12. The Human Papillomavirus E6 PDZ Binding Motif Links DNA Damage Response Signaling to E6 Inhibition of p53 Transcriptional Activity.
Thatte J; Massimi P; Thomas M; Boon SS; Banks L
J Virol; 2018 Aug; 92(16):. PubMed ID: 29848585
[TBL] [Abstract][Full Text] [Related]
13. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells.
Liu Y; Chen JJ; Gao Q; Dalal S; Hong Y; Mansur CP; Band V; Androphy EJ
J Virol; 1999 Sep; 73(9):7297-307. PubMed ID: 10438818
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification.
Hiller T; Poppelreuther S; Stubenrauch F; Iftner T
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1262-7. PubMed ID: 16835321
[TBL] [Abstract][Full Text] [Related]
15. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.
Crook T; Tidy JA; Vousden KH
Cell; 1991 Nov; 67(3):547-56. PubMed ID: 1657399
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus (HPV) 16 E6 sensitizes cells to atractyloside-induced apoptosis: role of p53, ICE-like proteases and the mitochondrial permeability transition.
Brown J; Higo H; McKalip A; Herman B
J Cell Biochem; 1997 Aug; 66(2):245-55. PubMed ID: 9213225
[TBL] [Abstract][Full Text] [Related]
17. Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein.
Eichten A; Westfall M; Pietenpol JA; Münger K
Virology; 2002 Mar; 295(1):74-85. PubMed ID: 12033767
[TBL] [Abstract][Full Text] [Related]
18. The effects of wild type p53 tumor suppressor gene expression on the normal human cervical epithelial cells or human epidermal keratinocytes transformed with human papillomavirus type 16 DNA.
Kim KH; Park TK; Yoon DJ; Kim YS
Yonsei Med J; 1995 Jul; 36(3):287-98. PubMed ID: 7660680
[TBL] [Abstract][Full Text] [Related]
19. The papillomavirus E6 proteins.
Rapp L; Chen JJ
Biochim Biophys Acta; 1998 Aug; 1378(1):F1-19. PubMed ID: 9739758
[TBL] [Abstract][Full Text] [Related]
20. Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.
Kehmeier E; Rühl H; Voland B; Stöppler MC; Androphy E; Stöppler H
Virology; 2002 Jul; 299(1):72-87. PubMed ID: 12167343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
